Abstract
The emergence of antibody-drug conjugates (ADCs) as a potential therapeutic avenue in cancer treatment has garnered significant attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drug molecules, ADCs aim to increase the therapeutic index, selectively targeting cancer cells while minimizing systemic toxicity. Various ADCs have been licensed for clinical usage, with ongoing research paving the way for additional options. However, the manufacture of ADCs faces several challenges. These include identifying suitable target antigens, enhancing antibodies, linkers, and payloads, and managing resistance mechanisms and side effects. This review focuses on the strategies to overcome these hurdles, such as site-specific conjugation techniques, novel antibody formats, and combination therapy. Our focus lies on current advancements in antibody engineering, linker technology, and cytotoxic payloads while addressing the challenges associated with ADC development. Furthermore, we explore the future potential of personalized medicine, leveraging individual patients’ molecular profiles, to propel ADC treatments forward. As our understanding of the molecular mechanisms driving cancer progression continues to expand, we anticipate the development of new ADCs that offer more effective and personalized therapeutic options for cancer patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, Mardaneh J, Farhadihosseinabadi B, Larki P, Faghfourian B, Sepehr KS, Abbaszadeh-Goudarzi K, Abbaszadeh-Goudarzi G, Johari B, Zali MR, Bagheri N (2019) Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes. J Cell Physiol 234:5628–5642. https://doi.org/10.1002/jcp.27419
Agarwal P, Bertozzi CR (2015) Site-specific antibody-drug conjugates the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem 26:176–192. https://doi.org/10.1021/bc5004982
Amyere M, Payrastre B, Krause U, Van Der Smissen P, Veithen A, Courtoy PJ (2000) Constitutive macropinocytosis in oncogene-transformed fibroblasts depends on sequential permanent activation of phosphoinositide 3-kinase and phospholipase C. Mol Biol Cell 11:3453–3467. https://doi.org/10.1091/mbc.11.10.3453
Andreev J, Thambi N, Perez Bay AE, Delfino F, Martin J, Kelly MP, Kirshner JR, Rafique A, Kunz A, Nittoli T, MacDonald D, Daly C, Olson W, Thurston G (2017) Bispecific Antibodies and antibody-drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs. Mol Cancer Ther 16:681–693. https://doi.org/10.1158/1535-7163.MCT-16-0658
Appenzeller-Herzog C, Ellgaard L (2008) The human PDI family: versatility packed into a single Fold. Biochim Biophys Acta 1783:535–548. https://doi.org/10.1016/j.bbamcr.2007.11.010
Armour KL, Clark MR, Hadley AG, Williamson LM (1999) Recombinant human IgG molecules lacking fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol 29:2613–2624. https://doi.org/10.1002/(SICI)1521-4141(199908)29:08%3C2613::AID-IMMU2613%3E3.0.CO;2-J
Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, Halder R, Forsyth JS, Santidrian AF, Stafin K, Lu Y, Tran H, Seller AJ, Biroc SL, Szydlik A, Pinkstaff JK, Tian F, Sinha SC, Felding-Habermann B, Smider VV, Schultz PG (2012) Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci USA 109:16101–16106. https://doi.org/10.1073/pnas.1211023109
Bakhtiar R (2016) Antibody-drug conjugates. Biotechnol Lett 38:1655–1664. https://doi.org/10.1007/s10529-016-2160-x
Bareford LM, Swaan PW (2007) Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 59:748–758. https://doi.org/10.1016/j.addr.2007.06.008
Bargh JD, Isidro-Llobet A, Parker JS, Spring DR (2019) Cleavable linkers in antibody-drug conjugates. Chem Soc Rev 48:4361–4374. https://doi.org/10.1039/c8cs00676h
Beck A, Goetsch L, Dumontet C, Corvaia N (2017) Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 16:315–337. https://doi.org/10.1038/nrd.2016.268
Behrens CR, Liu B (2014) Methods for site-specific drug conjugation to antibodies. MAbs 6:46–53. https://doi.org/10.4161/mabs.26632
Birrer MJ, Moore KN, Betella I, Bates RC (2019) Antibody-drug conjugate-based therapeutics: state of the Science. J Natl Cancer Inst 111:538–549. https://doi.org/10.1093/jnci/djz035
Bitsikas V, Correa IR Jr., Nichols BJ (2014) Clathrin-independent pathways do not contribute significantly to endocytic flux. Elife 3:e03970. https://doi.org/10.7554/eLife.03970
Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute Myeloid Leukemia. Clin Cancer Res 7:1490–1496
Burke PJ, Hamilton JZ, Pires TA, Setter JR, Hunter JH, Cochran JH, Waight AB, Gordon KA, Toki BE, Emmerton KK, Zeng W, Stone IJ, Senter PD, Lyon RP, Jeffrey SC (2016) Development of novel quaternary ammonium linkers for antibody-drug conjugates. Mol Cancer Ther 15:938–945. https://doi.org/10.1158/1535-7163.MCT-16-0038
Burke PJ, Hamilton JZ, Jeffrey SC, Hunter JH, Doronina SO, Okeley NM, Miyamoto JB, Anderson ME, Stone IJ, Ulrich ML, Simmons JK, McKinney EE, Senter PD, Lyon RP (2017) Optimization of a PEGylated glucuronide-monomethylauristatin E Linker for antibody-drug conjugates. Mol Cancer Ther 16:116–123. https://doi.org/10.1158/1535-7163.MCT-16-0343
Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L (2012) Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 12:615–622. https://doi.org/10.1016/j.coph.2012.08.001
Butler MS (2013) Remediating cancer via splicing modulation. J Med Chem 56:6573–6575. https://doi.org/10.1021/jm401289z
Cao W, Maza JC, Chernyak N, Flygare JA, Krska SW, Toste FD, Francis MB (2023) Modification of cysteine-substituted antibodies using enzymatic oxidative coupling reactions. Bioconjug Chem 34:510–517. https://doi.org/10.1021/acs.bioconjchem.2c00576
Carter KP, Deblonde GJ, Lohrey TD, Bailey TA, An DD, Shield KM, Lukens WW Jr., Abergel RJ (2020) Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals. Commun Chem 3:61. https://doi.org/10.1038/s42004-020-0307-0
Casi G, Neri D (2012) Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release 161:422–428. https://doi.org/10.1016/j.jconrel.2012.01.026
Casi G, Neri D (2015) Noninternalizing targeted cytotoxics for cancer therapy. Mol Pharm 12:1880–1884. https://doi.org/10.1021/mp500798y
Chalouni C, Doll S (2018) Fate of antibody-drug conjugates in Cancer cells. J Exp Clin Cancer Res 37:20. https://doi.org/10.1186/s13046-017-0667-1
Chari RV (1998) Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv Drug Deliv Rev 31:89–104. https://doi.org/10.1016/s0169-409x(97)00095-1
Chari RV (2008) Targeted cancer therapy: conferring specificity to cytotoxic Drugs. Acc Chem Res 41:98–107. https://doi.org/10.1021/ar700108g
Chiu ML, Goulet DR, Teplyakov A, Gilliland GL (2019) Antibody structure and function: the basis for engineering therapeutics. Antibodies (Basel). https://doi.org/10.3390/antib8040055
Chon H, Kanamori S, Hibino K, Nagahara T, Suzuki T, Ohara K, Narumi H (2023) ez-ADiCon: a novel glyco-remodeling based strategy that enables preparation of homogenous antibody-drug conjugates via one-step enzymatic transglycosylation with payload-preloaded bi-antennary glycan complexes. Bioorg Med Chem Lett 80:129117. https://doi.org/10.1016/j.bmcl.2022.129117
Chudasama V, Smith ME, Schumacher FF, Papaioannou D, Waksman G, Baker JR, Caddick S (2011) Bromopyridazinedione-mediated protein and peptide bioconjugation. Chem Commun (Camb) 47:8781–8783. https://doi.org/10.1039/c1cc12807h
Chudasama V, Maruani A, Caddick S (2016) Recent advances in the construction of antibody-drug conjugates. Nat Chem 8:114–119. https://doi.org/10.1038/nchem.2415
Criscitiello C, Morganti S, Curigliano G (2021) Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol 14:20. https://doi.org/10.1186/s13045-021-01035-z
Damelin M, Zhong W, Myers J, Sapra P (2015) Evolving strategies for target selection for antibody-drug conjugates. Pharm Res 32:3494–3507. https://doi.org/10.1007/s11095-015-1624-3
Dannheim FM, Walsh SJ, Orozco CT, Hansen AH, Bargh JD, Jackson SE, Bond NJ, Parker JS, Carroll JS, Spring DR (2022) All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading. Chem Sci 13:8781–8790. https://doi.org/10.1039/d2sc02198f
Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A (2017) Availability of evidence of benefits on overall survival and quality of life of cancer Drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ 359:j4530. https://doi.org/10.1136/bmj.j4530
de Cecco M, Galbraith DN, McDermott LL (2021) What makes a good antibody-drug conjugate? Expert Opin Biol Ther 21:841–847. https://doi.org/10.1080/14712598.2021.1880562
de Goeij BE, Vink T, Ten Napel H, Breij EC, Satijn D, Wubbolts R, Miao D, Parren PW (2016) Efficient payload delivery by a bispecific antibody-drug Conjugate Targeting HER2 and CD63. Mol Cancer Ther 15:2688–2697. https://doi.org/10.1158/1535-7163.MCT-16-0364
Deonarain MP, Yahioglu G (2021) Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy. Expert Opin Drug Discov 16:613–624. https://doi.org/10.1080/17460441.2021.1858050
Diamantis N, Banerji U (2016) Antibody-drug conjugates–an emerging class of cancer treatment. Br J Cancer 114:362–367. https://doi.org/10.1038/bjc.2015.435
Doherty GJ, McMahon HT (2009) Mechanisms of endocytosis. Annu Rev Biochem 78:857–902. https://doi.org/10.1146/annurev.biochem.78.081307.110540
Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, Wahl AF, Senter PD (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17:114–124. https://doi.org/10.1021/bc0502917
Dorywalska M, Strop P, Melton-Witt JA, Hasa-Moreno A, Farias SE, Galindo Casas M, Delaria K, Lui V, Poulsen K, Sutton J, Bolton G, Zhou D, Moine L, Dushin R, Tran TT, Liu SH, Rickert M, Foletti D, Shelton DL, Pons J, Rajpal A (2015) Site-dependent degradation of a non-cleavable auristatin-based linker-payload in Rodent plasma and its effect on ADC efficacy. PLoS ONE 10:e0132282. https://doi.org/10.1371/journal.pone.0132282
Dosio F, Brusa P, Cattel L (2011) Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel) 3:848–883. https://doi.org/10.3390/toxins3070848
Dubowchik GM, Firestone RA, Padilla L, Willner D, Hofstead SJ, Mosure K, Knipe JO, Lasch SJ, Trail PA (2002) Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem 13:855–869. https://doi.org/10.1021/bc025536j
Ducry L, Stump B (2010) Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 21:5–13. https://doi.org/10.1021/bc9002019
Eaton JS, Miller PE, Mannis MJ, Murphy CJ (2015) Ocular adverse events Associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther 31:589–604. https://doi.org/10.1089/jop.2015.0064
Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, Singh R (2010) Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 21:84–92. https://doi.org/10.1021/bc900315y
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pineros M, Znaor A, Bray F (2021) Cancer statistics for the year 2020: an overview. Int J Cancer. https://doi.org/10.1002/ijc.33588
Filntisi A, Vlachakis D, Matsopoulos GK, Kossida S (2014) Computational construction of antibody-drug Conjugates using Surface Lysines as the antibody conjugation site and a non-cleavable Linker. Cancer Inf 13:179–186. https://doi.org/10.4137/CIN.S19222
Firestone R, Willner D, Hofstead S, King H, Kaneko T, Braslawsky G, Greenfield R, Trail P, Lasch S, Henderson A (1996) Synthesis and antitumor activity of the immunoconjugate BR96-Dox. J Control Release 39:251–259. https://doi.org/10.1016/0168-3659(95)00160-3
Flygare JA, Pillow TH, Aristoff P (2013) Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des 81:113–121. https://doi.org/10.1111/cbdd.12085
Fu Z, Li S, Han S, Shi C, Zhang Y (2022) Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Ther 7:93. https://doi.org/10.1038/s41392-022-00947-7
Fujii T, Matsuda Y, Seki T, Shikida N, Iwai Y, Ooba Y, Takahashi K, Isokawa M, Kawaguchi S, Hatada N, Watanabe T, Takasugi R, Nakayama A, Shimbo K, Mendelsohn BA, Okuzumi T, Yamada K (2023) AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for antibody-drug Conjugate Production. Bioconjug Chem 34:728–738. https://doi.org/10.1021/acs.bioconjchem.3c00040
Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, Stelte-Ludwig B, Mayer-Bartschmid A, Unterschemmann K, Bruder S, Linden L, Harrenga A, Hauff P, Scholle FD, Muller-Tiemann B, Kreft B, Ziegelbauer K (2014) Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther 13:1537–1548. https://doi.org/10.1158/1535-7163.MCT-13-0926
Gondi CS, Rao JS (2013) Cathepsin B as a cancer target. Expert Opin Ther Targets 17:281–291. https://doi.org/10.1517/14728222.2013.740461
Goulet DR, Atkins WM (2020) Considerations for the design of antibody-based therapeutics. J Pharm Sci 109:74–103. https://doi.org/10.1016/j.xphs.2019.05.031
Hafeez U, Gan HK, Scott AM (2018) Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune Diseases. Curr Opin Pharmacol 41:114–121. https://doi.org/10.1016/j.coph.2018.05.010
Hafeez U, Parakh S, Gan HK, Scott AM (2020) Antibody-drug conjugates for cancer therapy. Molecules. https://doi.org/10.3390/molecules25204764
Hallam TJ, Wold E, Wahl A, Smider VV (2015) Antibody conjugates with unnatural amino acids. Mol Pharm 12:1848–1862. https://doi.org/10.1021/acs.molpharmaceut.5b00082
Hammood M, Craig AW, Leyton JV (2021) Impact of endocytosis mechanisms for the receptors targeted by the currently approved antibody-drug conjugates (ADCs)-a necessity for future ADC research and development. Pharmaceuticals (Basel) https://doi.org/10.3390/ph14070674
Hofer T, Skeffington LR, Chapman CM, Rader C (2009) Molecularly defined antibody conjugation through a selenocysteine interface. Biochemistry 48:12047–12057. https://doi.org/10.1021/bi901744t
Hoffmann RM, Coumbe BGT, Josephs DH, Mele S, Ilieva KM, Cheung A, Tutt AN, Spicer JF, Thurston DE, Crescioli S, Karagiannis SN (2018) Antibody structure and engineering considerations for the design and function of antibody drug conjugates (ADCs). Oncoimmunology 7:e1395127. https://doi.org/10.1080/2162402X.2017.1395127
Hoos A (2016) Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 15:235–247. https://doi.org/10.1038/nrd.2015.35
Iqbal N, Iqbal N (2014) Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014:852748. https://doi.org/10.1155/2014/852748
Jager S, Wagner TR, Rasche N, Kolmar H, Hecht S, Schroter C (2021) Generation and Biological evaluation of fc Antigen binding fragment-drug conjugates as a novel antibody-based format for targeted drug delivery. Bioconjug Chem 32:1699–1710. https://doi.org/10.1021/acs.bioconjchem.1c00240
Jain KK (2021) Personalized Immuno-Oncology. Med Princ Pract 30:1–16. https://doi.org/10.1159/000511107
Jaramillo ML, Sulea T, Durocher Y, Acchione M, Schur MJ, Robotham A, Kelly JF, Goneau MF, Robert A, Cepero-Donates Y, Gilbert M (2023) A glyco-engineering approach for site-specific conjugation to Fab glycans. MAbs 15:2149057. https://doi.org/10.1080/19420862.2022.2149057
Johansson L, Gafvelin G, Arner ES (2005) Selenocysteine in proteins-properties and biotechnological use. Biochim Biophys Acta 1726:1–13. https://doi.org/10.1016/j.bbagen.2005.05.010
Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925–932. https://doi.org/10.1038/nbt.1480
Kalim M, Chen J, Wang S, Lin C, Ullah S, Liang K, Ding Q, Chen S, Zhan J (2017) Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates. Drug Des Devel Ther 11:2265–2276. https://doi.org/10.2147/DDDT.S135571
Kalinovsky DV, Kibardin AV, Kholodenko IV, Svirshchevskaya EV, Doronin II, Konovalova MV, Grechikhina MV, Rozov FN, Larin SS, Deyev SM, Kholodenko RV (2022) Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors. J Immunother Cancer. https://doi.org/10.1136/jitc-2022-004646
Kamath AV, Iyer S (2015) Preclinical pharmacokinetic considerations for the development of antibody drug conjugates. Pharm Res 32:3470–3479. https://doi.org/10.1007/s11095-014-1584-z
Kaur G, Hollingshead M, Holbeck S, Schauer-Vukasinovic V, Camalier RF, Domling A, Agarwal S (2006) Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product. Biochem J 396:235–242. https://doi.org/10.1042/BJ20051735
Kern JC, Cancilla M, Dooney D, Kwasnjuk K, Zhang R, Beaumont M, Figueroa I, Hsieh S, Liang L, Tomazela D, Zhang J, Brandish PE, Palmieri A, Stivers P, Cheng M, Feng G, Geda P, Shah S, Beck A, Bresson D, Firdos J, Gately D, Knudsen N, Manibusan A, Schultz PG, Sun Y, Garbaccio RM (2016) Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal linkers for site-specific antibody-drug conjugates. J Am Chem Soc 138:1430–1445. https://doi.org/10.1021/jacs.5b12547
Khera E, Thurber GM (2018) Pharmacokinetic and immunological considerations for expanding the therapeutic window of next-generation antibody-drug conjugates. BioDrugs 32:465–480. https://doi.org/10.1007/s40259-018-0302-5
Khoshnejad M, Brenner JS, Motley W, Parhiz H, Greineder CF, Villa CH, Marcos-Contreras OA, Tsourkas A, Muzykantov VR (2018) Molecular engineering of antibodies for site-specific covalent conjugation using CRISPR/Cas9. Sci Rep 8:1760. https://doi.org/10.1038/s41598-018-19784-2
Kim EG, Kim KM (2015) Strategies and Advancement in Antibody-Drug Conjugate optimization for targeted Cancer therapeutics. Biomol Ther (Seoul) 23:493–509. https://doi.org/10.4062/biomolther.2015.116
Knaus UG, Wang Y, Reilly AM, Warnock D, Jackson JH (1998) Structural requirements for PAK activation by Rac GTPases. J Biol Chem 273:21512–21518. https://doi.org/10.1074/jbc.273.34.21512
Koga S, Oshima Y, Honkura N, Iimura T, Kameda K, Sato K, Yoshida M, Yamamoto Y, Watanabe Y, Hikita A, Imamura T (2014) In vivo subcellular imaging of tumors in mouse models using a fluorophore-conjugated anti-carcinoembryonic antigen antibody in two-photon excitation microscopy. Cancer Sci 105:1299–1306. https://doi.org/10.1111/cas.12500
Kostova V, Désos P, Starck J-B, Kotschy A (2021) The chemistry behind ADCs. Pharmaceuticals 14:442. https://doi.org/10.3390/ph14050442
Kovtun YV, Goldmacher VS (2007) Cell killing by antibody-drug conjugates. Cancer Lett 255:232–240. https://doi.org/10.1016/j.canlet.2007.04.010
Lai Q, Wu M, Wang R, Lai W, Tao Y, Lu Y, Wang Y, Yu L, Zhang R, Peng Y (2020) Cryptophycin-55/52 based antibody-drug conjugates: synthesis, efficacy, and mode of action studies. Eur J Med Chem 199:112364. https://doi.org/10.1016/j.ejmech.2020.112364
Lamb YN (2017) Inotuzumab Ozogamicin: First Global approval. Drugs 77:1603–1610. https://doi.org/10.1007/s40265-017-0802-5
Lambert JM, Chari RV (2014) Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive Breast cancer. J Med Chem 57:6949–6964. https://doi.org/10.1021/jm500766w
Le Gall CM, van der Schoot JMS, Ramos-Tomillero I, Khalily MP, van Dalen FJ, Wijfjes Z, Smeding L, van Dalen D, Cammarata A, Bonger KM, Figdor CG, Scheeren FA, Verdoes M (2021) Dual site-specific chemoenzymatic antibody fragment conjugation using CRISPR-Based Hybridoma Engineering. Bioconjug Chem 32:301–310. https://doi.org/10.1021/acs.bioconjchem.0c00673
Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX (2008) Targeting HER2-positive Breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280–9290. https://doi.org/10.1158/0008-5472.CAN-08-1776
Li R, Attari A, Prytyskach M, Garlin MA, Weissleder R, Miller MA (2020) Single-cell Intravital Microscopy of Trastuzumab quantifies heterogeneous in vivo kinetics. Cytometry A 97:528–539. https://doi.org/10.1002/cyto.a.23872
Liang K, Mei S, Gao X, Peng S, Zhan J (2021) Dynamics of endocytosis and degradation of antibody-drug conjugate T-DM1 in HER2 positive Cancer cells. Drug Des Devel Ther 15:5135–5150. https://doi.org/10.2147/DDDT.S344052
Liberatore FA, Comeau RD, McKearin JM, Pearson DA, Belonga BQ 3rd, Brocchini SJ, Kath J, Phillips T, Oswell K, Lawton RG (1990) Site-directed chemical modification and cross-linking of a monoclonal antibody using equilibrium transfer alkylating cross-link reagents. Bioconjug Chem 1:36–50. https://doi.org/10.1021/bc00001a005
Lin K, Tibbitts J (2012) Pharmacokinetic considerations for antibody drug conjugates. Pharm Res 29:2354–2366. https://doi.org/10.1007/s11095-012-0800-y
Lipman NS, Jackson LR, Trudel LJ, Weis-Garcia F (2005) Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. ILAR J 46:258–268. https://doi.org/10.1093/ilar.46.3.258
Liu X, Biswas S, Berg MG, Antapli CM, Xie F, Wang Q, Tang MC, Tang GL, Zhang L, Dreyfuss G, Cheng YQ (2013) Genomics-guided discovery of thailanstatins a, B, and C as pre-mRNA splicing inhibitors and antiproliferative agents from Burkholderia thailandensis MSMB43. J Nat Prod 76:685–693. https://doi.org/10.1021/np300913h
Liu R, Wang RE, Wang F (2016) Antibody-drug conjugates for non-oncological indications. Expert Opin Biol Ther 16:591–593. https://doi.org/10.1517/14712598.2016.1161753
Liu H, Bolleddula J, Nichols A, Tang L, Zhao Z, Prakash C (2020) Metabolism of bioconjugate therapeutics: why, when, and how? Drug Metab Rev 52:66–124. https://doi.org/10.1080/03602532.2020.1716784
Loganzo F, Sung M, Gerber HP (2016) Mechanisms of resistance to antibody-drug conjugates. Mol Cancer Ther 15:2825–2834. https://doi.org/10.1158/1535-7163.MCT-16-0408
Lopus M (2011) Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett 307:113–118. https://doi.org/10.1016/j.canlet.2011.03.017
Lopus M (2022) Shooting Cancer with magic bullets. Resonance 27:1127–1130. https://doi.org/10.1007/s12045-022-1409-z
LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX (2011) Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 17:6437–6447. https://doi.org/10.1158/1078-0432.CCR-11-0762
Lyon RP, Meyer DL, Setter JR, Senter PD (2012) Conjugation of anticancer Drugs through endogenous monoclonal antibody cysteine residues. Methods Enzymol 502:123–138. https://doi.org/10.1016/B978-0-12-416039-2.00006-9
Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, Jonas M, Anderson ME, Setter JR, Senter PD (2015) Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol 33:733–735. https://doi.org/10.1038/nbt.3212
Lyons SK, Plenker D, Trotman LC (2021) Advances in preclinical evaluation of experimental antibody-drug conjugates. Cancer Drug Resist 4:745–754. https://doi.org/10.20517/cdr.2021.37
Maiti R, Patel B, Patel N, Patel M, Patel A, Dhanesha N (2023) Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities. Arch Pharm Res 46:361–388. https://doi.org/10.1007/s12272-023-01447-0
Mantaj J, Jackson PJ, Rahman KM, Thurston DE (2017) From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing antibody-drug conjugates (ADCs). Angew Chem Int Ed Engl 56:462–488. https://doi.org/10.1002/anie.201510610
May JP, Perrin DM (2008) Intraannular Savige-Fontana reaction: one-step conversion of one class of monocyclic peptides into another class of bicyclic peptides. Chemistry 14:3404–3409. https://doi.org/10.1002/chem.200701088
McCombs JR, Owen SC (2015) Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J 17:339–351. https://doi.org/10.1208/s12248-014-9710-8
Mueller BM, Wrasidlo WA, Reisfeld RA (1990) Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers. Bioconjug Chem 1:325–330. https://doi.org/10.1021/bc00005a005
Mukherjee S, Bhatti GK, Chhabra R, Reddy PH, Bhatti JS (2023) Targeting mitochondria as a potential therapeutic strategy against chemoresistance in cancer. Biomed Pharmacother 160:114398. https://doi.org/10.1016/j.biopha.2023.114398
Myers SM, Collins I (2016) Recent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapy. Future Med Chem 8:463–489. https://doi.org/10.4155/fmc.16.5
Nejadmoghaddam MR, Minai-Tehrani A, Ghahremanzadeh R, Mahmoudi M, Dinarvand R, Zarnani AH (2019) Antibody-drug conjugates: possibilities and challenges. Avicenna J Med Biotechnol 11:3–23
Nilchan N, Li X, Pedzisa L, Nanna AR, Roush WR, Rader C (2019) Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine/cysteine conjugation. Antib Ther 2:71–78. https://doi.org/10.1093/abt/tbz009
Nolting B (2013) Linker technologies for antibody-drug conjugates. Methods Mol Biol 1045:71–100. https://doi.org/10.1007/978-1-62703-541-5_5
Pahl A, Lutz C, Hechler T (2018) Amanitins and their development as a payload for antibody-drug conjugates. Drug Discov Today Technol 30:85–89. https://doi.org/10.1016/j.ddtec.2018.08.005
Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR (2014) Site-specific antibody drug conjugates for cancer therapy. MAbs. https://doi.org/10.4161/mabs.27022
Park JH, Pyun WY, Park HW (2020) Cancer metabolism: phenotype, signaling and therapeutic targets. Cells. https://doi.org/10.3390/cells9102308
Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM (2014) Antibody-drug conjugates: current status and future directions. Drug Discov Today 19:869–881. https://doi.org/10.1016/j.drudis.2013.11.004
Peters C, Brown S (2015) Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. https://doi.org/10.1042/BSR20150089
Pillow TH, Adhikari P, Blake RA, Chen J, Del Rosario G, Deshmukh G, Figueroa I, Gascoigne KE, Kamath AV, Kaufman S, Kleinheinz T, Kozak KR, Latifi B, Leipold DD, Sing Li C, Li R, Mulvihill MM, O’Donohue A, Rowntree RK, Sadowsky JD, Wai J, Wang X, Wu C, Xu Z, Yao H, Yu SF, Zhang D, Zang R, Zhang H, Zhou H, Zhu X, Dragovich PS (2020) Antibody conjugation of a chimeric BET degrader enables in vivo activity. ChemMedChem 15:17–25. https://doi.org/10.1002/cmdc.201900497
Polson AG, Ho WY, Ramakrishnan V (2011) Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs 20:75–85. https://doi.org/10.1517/13543784.2011.539557
Ponziani S, Di Vittorio G, Pitari G, Cimini AM, Ardini M, Gentile R, Iacobelli S, Sala G, Capone E, Flavell DJ (2020) Antibody-drug conjugates: the new frontier of chemotherapy. Int J Mol Sci 21:5510. https://doi.org/10.3390/ijms21155510
Puthenveetil S, Loganzo F, He H, Dirico K, Green M, Teske J, Musto S, Clark T, Rago B, Koehn F, Veneziale R, Falahaptisheh H, Han X, Barletta F, Lucas J, Subramanyam C, O’Donnell CJ, Tumey LN, Sapra P, Gerber HP, Ma D, Graziani EI (2016) Natural product splicing inhibitors: a new class of antibody-drug conjugate (ADC) payloads. Bioconjug Chem 27:1880–1888. https://doi.org/10.1021/acs.bioconjchem.6b00291
Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, Burnett AK, Kantarjian HM (2012) Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol 30:3921–3923. https://doi.org/10.1200/JCO.2012.43.0132
Redman JM, Hill EM, AlDeghaither D, Weiner LM (2015) Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol 67:28–45. https://doi.org/10.1016/j.molimm.2015.04.002
Rees AR (2015) The antibody molecule: from antitoxins to therapeutic antibodies. Oxford Medical Histories, Oxford
Reichert JM, Valge-Archer VE (2007) Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6:349–356. https://doi.org/10.1038/nrd2241
Ritchie M, Tchistiakova L, Scott N (2013) Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs 5:13–21. https://doi.org/10.4161/mabs.22854
Ritchie M, Bloom L, Carven G, Sapra P (2015) Selecting an optimal antibody for antibody- drug Conjugate Therapy. In: Wang J, Shen W-C, Zaro JL (eds) Antibody-drug conjugates: the 21st century magic bullets for Cancer. Springer International Publishing, Cham. https://doi.org/10.1007/978-3-319-13081-1_3
Rohrer T (2017) Manufacturing concepts for antibody–drug conjugates. Process Scale Purif Antibodies. https://doi.org/10.1002/9781119126942.ch27
Roopenian DC, Akilesh S (2007) FcRn: the neonatal fc receptor comes of age. Nat Rev Immunol 7:715–725. https://doi.org/10.1038/nri2155
Samantasinghar A, Sunildutt NP, Ahmed F, Soomro AM, Salih ARC, Parihar P, Memon FH, Kim KH, Kang IS, Choi KH (2023) A comprehensive review of key factors affecting the efficacy of antibody drug conjugate. Biomed Pharmacother 161:114408. https://doi.org/10.1016/j.biopha.2023.114408
Saunders KO (2019) Conceptual approaches to modulating antibody effector functions and circulation half-life. Front Immunol 10:1296. https://doi.org/10.3389/fimmu.2019.01296
Schettini F, Barbao P, Braso-Maristany F, Galvan P, Martinez D, Pare L, De Placido S, Prat A, Guedan S (2021) Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in Breast cancer. ESMO Open 6:100102. https://doi.org/10.1016/j.esmoop.2021.100102
Schroder BA, Wrocklage C, Hasilik A, Saftig P (2010) The proteome of lysosomes. Proteomics 10:4053–4076. https://doi.org/10.1002/pmic.201000196
Schwach J, Abdellatif M, Stengl A (2022) More than toxins-current prospects in Designing the next generation of antibody drug conjugates. Front Biosci (Landmark Ed) 27:240. https://doi.org/10.31083/j.fbl2708240
Senter PD (2009) Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 13:235–244. https://doi.org/10.1016/j.cbpa.2009.03.023
Shao T, Chen T, Chen Y, Liu X, Chen YL, Wang Q, Zhu T, Guo M, Li H, Ju D, Wang C (2020) Construction of paclitaxel-based antibody-drug conjugates with a PEGylated linker to achieve superior therapeutic index. Signal Transduct Target Ther 5:132. https://doi.org/10.1038/s41392-020-00247-y
Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, Li D, Tibbitts J, Baudys J, Saad OM, Scales SJ, McDonald PJ, Hass PE, Eigenbrot C, Nguyen T, Solis WA, Fuji RN, Flagella KM, Patel D, Spencer SD, Khawli LA, Ebens A, Wong WL, Vandlen R, Kaur S, Sliwkowski MX, Scheller RH, Polakis P, Junutula JR (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 30:184–189. https://doi.org/10.1038/nbt.2108
Siegel MM, Tabei K, Kunz A, Hollander IJ, Hamann RR, Bell DH, Berkenkamp S, Hillenkamp F (1997) Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry. Anal Chem 69:2716–2726. https://doi.org/10.1021/ac970035q
Sievers EL, Senter PD (2013) Antibody-drug conjugates in cancer therapy. Annu Rev Med 64:15–29. https://doi.org/10.1146/annurev-med-050311-201823
Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR, Mylotarg Study G (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute Myeloid Leukemia in first relapse. J Clin Oncol 19:3244–3254. https://doi.org/10.1200/JCO.2001.19.13.3244
Simmons JK, Burke PJ, Cochran JH, Pittman PG, Lyon RP (2020) Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation. Toxicol Appl Pharmacol 392:114932. https://doi.org/10.1016/j.taap.2020.114932
Singh AP, Guo L, Verma A, Wong GG, Thurber GM, Shah DK (2020) Antibody coadministration as a strategy to overcome binding-site barrier for ADCs: a quantitative investigation. AAPS J 22:28. https://doi.org/10.1208/s12248-019-0387-x
Smith ME, Schumacher FF, Ryan CP, Tedaldi LM, Papaioannou D, Waksman G, Caddick S, Baker JR (2010) Protein modification, bioconjugation, and disulfide bridging using bromomaleimides. J Am Chem Soc 132:1960–1965. https://doi.org/10.1021/ja908610s
Solomon A, Weiss DT (1995) Structural and functional properties of human lambda-light-chain variable-region subgroups. Clin Diagn Lab Immunol 2:387–394. https://doi.org/10.1128/cdli.2.4.387-394.1995
Staudacher AH, Li Y, Liapis V, Hou JJC, Chin D, Dolezal O, Adams TE, van Berkel PH, Brown MP (2019) APOMAB antibody-drug Conjugates Targeting Dead Tumor cells are effective in vivo. Mol Cancer Ther 18:335–345. https://doi.org/10.1158/1535-7163.MCT-18-0842
Strohl WR (2018) Current progress in innovative engineered antibodies. Protein Cell 9:86–120. https://doi.org/10.1007/s13238-017-0457-8
Strop P, Delaria K, Foletti D, Witt JM, Hasa-Moreno A, Poulsen K, Casas MG, Dorywalska M, Farias S, Pios A, Lui V, Dushin R, Zhou D, Navaratnam T, Tran TT, Sutton J, Lindquist KC, Han B, Liu SH, Shelton DL, Pons J, Rajpal A (2015) Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat Biotechnol 33:694–696. https://doi.org/10.1038/nbt.3274
Subhan MA, Parveen F, Shah H, Yalamarty SSK, Ataide JA, Torchilin VP (2023) Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type. Cancers (Basel). https://doi.org/10.3390/cancers15082204
Tang H, Liu Y, Yu Z, Sun M, Lin L, Liu W, Han Q, Wei M, Jin Y (2019) The analysis of key factors related to ADCs Structural Design. Front Pharmacol 10:373. https://doi.org/10.3389/fphar.2019.00373
Tapia-Galisteo A, Compte M, Alvarez-Vallina L, Sanz L (2023) When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy. Theranostics 13:1028–1041. https://doi.org/10.7150/thno.81494
Tarantino P, Tolaney SM (2022) The Dawn of the antibody-drug conjugates era: how T-DM1 reinvented the future of chemotherapy for solid tumors. Cancer Res 82:3659–3661. https://doi.org/10.1158/0008-5472.CAN-22-2324
Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, Cortes J, Soria JC, Curigliano G (2022) Antibody-drug conjugates: Smart chemotherapy delivery across Tumor histologies. CA Cancer J Clin 72:165–182. https://doi.org/10.3322/caac.21705
Thevanayagam L, Bell A, Chakraborty I, Sufi B, Gangwar S, Zang A, Rangan V, Rao C, Wang Z, Pan C, Chong C, Cardarelli P, Deshpande S, Srinivasan M (2013) Novel detection of DNA-alkylated adducts of antibody-drug conjugates with potentially unique preclinical and biomarker applications. Bioanalysis 5:1073–1081. https://doi.org/10.4155/bio.13.57
Thoreau F, Rochet LNC, Baker JR, Chudasama V (2023) Enabling the formation of native mAb, Fab’ and Fc-conjugates using a bis-disulfide bridging reagent to achieve tunable payload-to-antibody ratios (PARs). Chem Sci 14:3752–3762. https://doi.org/10.1039/d2sc06318b
Tranoy-Opalinski I, Legigan T, Barat R, Clarhaut J, Thomas M, Renoux B, Papot S (2014) beta-glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update. Eur J Med Chem 74:302–313. https://doi.org/10.1016/j.ejmech.2013.12.045
Tsao LC, Force J, Hartman ZC (2021) Mechanisms of Therapeutic Antitumor Monoclonal antibodies. Cancer Res 81:4641–4651. https://doi.org/10.1158/0008-5472.CAN-21-1109
Tsuchikama K, An Z (2018) Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 9:33–46. https://doi.org/10.1007/s13238-016-0323-0
Tsui CK, Barfield RM, Fischer CR, Morgens DW, Li A, Smith BAH, Gray MA, Bertozzi CR, Rabuka D, Bassik MC (2019) CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity. Nat Chem Biol 15:949–958. https://doi.org/10.1038/s41589-019-0342-2
Tsumura R, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y (2018) Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor. J Control Release 284:49–56. https://doi.org/10.1016/j.jconrel.2018.06.016
van de Donk NW, Dhimolea E (2012) Brentuximab vedotin. MAbs 4:458–465. https://doi.org/10.4161/mabs.20230
van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, van Dongen JJ (2001) Targeting of the CD33-calicheamicin immunoconjugate mylotarg (CMA-676) in acute Myeloid Leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97:3197–3204. https://doi.org/10.1182/blood.v97.10.3197
Veithen A, Cupers P, Baudhuin P, Courtoy PJ (1996) v-Src induces constitutive macropinocytosis in rat fibroblasts. J Cell Sci 109(Pt 8):2005–2012. https://doi.org/10.1242/jcs.109.8.2005
Voskuil FJ, de Jongh SJ, Hooghiemstra WTR, Linssen MD, Steinkamp PJ, de Visscher S, Schepman KP, Elias SG, Meersma GJ, Jonker PKC, Doff JJ, Jorritsma-Smit A, Nagengast WB, van der Vegt B, Robinson DJ, van Dam GM, Witjes MJH (2020) Fluorescence-guided imaging for resection margin evaluation in Head and Neck cancer patients using cetuximab-800CW: a quantitative dose-escalation study. Theranostics 10:3994–4005. https://doi.org/10.7150/thno.43227
Vu T, Claret FX (2012) Trastuzumab: updated mechanisms of action and resistance in Breast cancer. Front Oncol 2:62. https://doi.org/10.3389/fonc.2012.00062
Walton JD, Hallen-Adams HE, Luo H (2010) Ribosomal biosynthesis of the cyclic peptide toxins of Amanita mushrooms. Biopolymers 94:659–664. https://doi.org/10.1002/bip.21416
Wang L, Amphlett G, Blattler WA, Lambert JM, Zhang W (2005) Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 14:2436–2446. https://doi.org/10.1110/ps.051478705
Wang YJ, Li YY, Liu XY, Lu XL, Cao X, Jiao BH (2017) Marine Antibody-Drug Conjugates: Design Strategies and Research Progress. Mar Drugs. https://doi.org/10.3390/md15010018
Weiner GJ (2015) Building better monoclonal antibody-based therapeutics. Nat Rev Cancer 15:361–370. https://doi.org/10.1038/nrc3930
Weiner LM, Murray JC, Shuptrine CW (2012) Antibody-based immunotherapy of cancer. Cell 148:1081–1084. https://doi.org/10.1016/j.cell.2012.02.034
Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, Goldmacher VS, Xie H, Steeves RM, Lutz RJ, Zhao R, Wang L, Blattler WA, Chari RV (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49:4392–4408. https://doi.org/10.1021/jm060319f
Wu AM, Senter PD (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137–1146. https://doi.org/10.1038/nbt1141
Wu G, Fang YZ, Yang S, Lupton JR, Turner ND (2004) Glutathione metabolism and its implications for health. J Nutr 134:489–492. https://doi.org/10.1093/jn/134.3.489
Wu P, Shui W, Carlson BL, Hu N, Rabuka D, Lee J, Bertozzi CR (2009) Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag. Proc Natl Acad Sci U S A 106:3000–3005. https://doi.org/10.1073/pnas.0807820106
Wu L, Seung E, Xu L, Rao E, Lord DM, Wei RR, Cortez-Retamozo V, Ospina B, Posternak V, Ulinski G (2020) Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat Cancer 1:86–98. https://doi.org/10.1038/s43018-019-0004-z
Xu S (2015) Internalization, trafficking, Intracellular Processing and actions of antibody-drug conjugates. Pharm Res 32:3577–3583. https://doi.org/10.1007/s11095-015-1729-8
Yaghoubi S, Karimi MH, Lotfinia M, Gharibi T, Mahi-Birjand M, Kavi E, Hosseini F, Sineh Sepehr K, Khatami M, Bagheri N, Abdollahpour-Alitappeh M (2020) Potential Drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy. J Cell Physiol 235:31–64. https://doi.org/10.1002/jcp.28967
Yamazaki CM, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J, Ueno NT, Zhang N, An Z, Tsuchikama K (2021) Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun 12:3528. https://doi.org/10.1038/s41467-021-23793-7
Yang H, Ganguly A, Cabral F (2010) Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting Drugs. J Biol Chem 285:32242–32250. https://doi.org/10.1074/jbc.M110.160820
Yao X, Jiang J, Wang X, Huang C, Li D, Xie K, Xu Q, Li H, Li Z, Lou L, Fang J (2015) A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. Breast Cancer Res Treat 153:123–133. https://doi.org/10.1007/s10549-015-3503-3
Yoon JK, Park BN, Ryu EK, An YS, Lee SJ (2020) Current perspectives on (89)Zr-PET imaging. Int J Mol Sci. https://doi.org/10.3390/ijms21124309
Zhang J, Zhang X, Liu G, Chang D, Liang X, Zhu X, Tao W, Mei L (2016) Intracellular Trafficking Network of Protein Nanocapsules: endocytosis, exocytosis and autophagy. Theranostics 6:2099–2113. https://doi.org/10.7150/thno.16587
Zhang C, Zhang Y, Hong K, Zhu S, Wan J (2017) Photoacoustic and Fluorescence Imaging of Cutaneous Squamous Cell Carcinoma in living subjects using a probe targeting integrin alpha(v)beta(6). Sci Rep 7:42442. https://doi.org/10.1038/srep42442
Zhao H, Lee C, Sai P, Choe YH, Boro M, Pendri A, Guan S, Greenwald RB (2000) 20-O-acylcamptothecin derivatives: evidence for lactone stabilization. J Org Chem 65:4601–4606. https://doi.org/10.1021/jo000221n
Zhao P, Zhang Y, Li W, Jeanty C, Xiang G, Dong Y (2020) Recent advances of antibody-drug conjugates for clinical applications. Acta Pharm Sin B 10:1589–1600. https://doi.org/10.1016/j.apsb.2020.04.012
Acknowledgements
This research has been supported by the Science and Engineering Research Board (SERB), India (EEQ/2020/000188). BioRender software was used to create the figures appended in this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declared no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kumari, S., Raj, S., Babu, M.A. et al. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions. Arch. Pharm. Res. 47, 40–65 (2024). https://doi.org/10.1007/s12272-023-01479-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-023-01479-6